Literature DB >> 8562291

Zidovudine therapy in HIV infection: which patients should be treated and when.

M G Barry1, D J Back, A M Breckenridge.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8562291      PMCID： PMC1365168          DOI： 10.1111/j.1365-2125.1995.tb05765.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  35 in total

1.  Reducing the risk of maternal-infant transmission of HIV: a door is opened.

Authors:  M F Rogers; H W Jaffe
Journal:  N Engl J Med       Date:  1994-11-03       Impact factor: 91.245

2.  Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. The European-Australian Collaborative Group.

Authors:  D A Cooper; J M Gatell; S Kroon; N Clumeck; J Millard; F D Goebel; J N Bruun; G Stingl; R L Melville; J González-Lahoz
Journal:  N Engl J Med       Date:  1993-07-29       Impact factor: 91.245

3.  Alternating and intermittent regimens of zidovudine and dideoxycytidine in patients with AIDS or AIDS-related complex.

Authors:  G Skowron; S A Bozzette; L Lim; C B Pettinelli; H H Schaumburg; J Arezzo; M A Fischl; W G Powderly; D J Gocke; D D Richman; J C Pottage; D Antoniskis; G F McKinley; N E Hyslop; G Ray; G Simon; N Reed; M L LoFaro; R B Uttamchandani; L D Gelb; S J Sperber; R L Murphy; J M Leedom; M H Grieco; J Zachary; M S Hirsch; S A Spector; J Bigley; W Soo; T C Merigan
Journal:  Ann Intern Med       Date:  1993-03-01       Impact factor: 25.391

4.  Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.

Authors:  E M Connor; R S Sperling; R Gelber; P Kiselev; G Scott; M J O'Sullivan; R VanDyke; M Bey; W Shearer; R L Jacobson
Journal:  N Engl J Med       Date:  1994-11-03       Impact factor: 91.245

5.  A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. Results of the Veterans Affairs Cooperative Study.

Authors:  J D Hamilton; P M Hartigan; M S Simberkoff; P L Day; G R Diamond; G M Dickinson; G L Drusano; M J Egorin; W L George; F M Gordin
Journal:  N Engl J Med       Date:  1992-02-13       Impact factor: 91.245

6.  The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.

Authors:  M A Fischl; D D Richman; M H Grieco; M S Gottlieb; P A Volberding; O L Laskin; J M Leedom; J E Groopman; D Mildvan; R T Schooley
Journal:  N Engl J Med       Date:  1987-07-23       Impact factor: 91.245

Review 7.  Combination therapy for infection due to human immunodeficiency virus type 1.

Authors:  A M Caliendo; M S Hirsch
Journal:  Clin Infect Dis       Date:  1994-04       Impact factor: 9.079

8.  Zidovudine twice daily in asymptomatic subjects with HIV infection and a high risk of progression to AIDS: a randomized, double-blind placebo-controlled study. The European-Australian Collaborative Group (Study 017)

Authors:  J W Mulder; D A Cooper; L Mathiesen; E Sandström; N Clumeck; J M Gatell; M French; B Donovan; F Gray; J M Yeo
Journal:  AIDS       Date:  1994-03       Impact factor: 4.177

9.  Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy.

Authors:  Y K Chow; M S Hirsch; D P Merrill; L J Bechtel; J J Eron; J C Kaplan; R T D'Aquila
Journal:  Nature       Date:  1993-02-18       Impact factor: 49.962

10.  Evaluation of the quality of life associated with zidovudine treatment in asymptomatic human immunodeficiency virus infection. The AIDS Clinical Trials Group.

Authors:  W R Lenderking; R D Gelber; D J Cotton; B F Cole; A Goldhirsch; P A Volberding; M A Testa
Journal:  N Engl J Med       Date:  1994-03-17       Impact factor: 91.245
View more
  1 in total

Review 1.  Antiretroviral therapy for patients with HIV disease.

Authors:  M Barry; F Mulcahy; D J Back
Journal:  Br J Clin Pharmacol       Date:  1998-03       Impact factor: 4.335
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.